VExUS Combined With CVP to Predict Clinical Outcomes in Sepsis Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction:

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and it is a common critical condition in the ICU. Early and timely fluid resuscitation is the cornerstone of sepsis treatment. However, excessive fluid loading can lead to interstitial edema and iatrogenic organ damage, particularly acute kidney injury (AKI). The VExUS grading system is a recently developed system that measures venous congestion through bedside ultrasound by assessing the blood flow waveforms of the portal vein, hepatic vein, and intrarenal veins, as well as the diameter of the inferior vena cava. Similarly, CVP is a commonly used indicator of venous congestion. The objective of this study is to Investigate the association between Venous Excess Ultrasound Score (VExUS), Central Venous Pressure (CVP) during the first three days of ICU admission, and the composite clinical outcome of major adverse kidney events within 30 days (MAKE 30) in sepsis participants.

Methods:

This study is a prospective, multicenter, observational study that will recruit at least 120 participants across multiple centers. Based on the definition of sepsis3.0, Participants with sepsis who are older than 18 years. Using Doppler ultrasound, Investigator will measure the IVC, HV, PV, and IRV, as well as lung ultrasound scores and cardiac-related parameters at 0-24 hours, 24-48 hours, and 48-72 hours after enrollment. Investigator will receive web-based educational courses, and image acquisition and interpretation will be adjudicated. The primary outcome is the relationship between VExUS score combined with CVP and MAKE 30 in sepsis participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VExUS in Ards Patients and Association with AKI

NCT06805409

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

RECRUITING

Treatment According to Venous Excess Ultrasound Score in Patients With Heart Failure

NCT06341816

Heart Failure Acute Kidney Injury

NOT_YET_RECRUITING NA

Prevalence of Venous conGestion and Its Association With Renal Injuries Evaluated by the VExUS Score On Admission With UltraSound in Patients With Cardiogenic Pulmonary Edema

NCT05881603

Cardiogenic Acute Pulmonary Edema

UNKNOWN

Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient

NCT02638350

Pulmonary Edema Respiratory Distress Syndrome

COMPLETED NA

Predictive Value of Venous Excess Ultrasound Score in Management of Cardiorenal Patients

NCT05368766

Cardio-Renal Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Title:

Association between VExUS Score Combined with CVP and Prediction of Clinical Outcomes in Septic participants: A Multicenter, Prospective, Observational Study.

Study Objective:

To investigate the relationship between VExUS score, CVP within the first 3 days of ICU admission in septic participants, and the composite clinical outcome of major kidney adverse events within 30 days (MAKE30).

Study Hypothesis:

The VExUS score and CVP in septic participants are related to the composite clinical outcome of major kidney adverse events within 30 days (MAKE 30), and the higher the VExUS score and CVP, the greater the risk of MAKE 30.

Outcome Measures:

Primary Outcome: Association between VExUS score, CVP, and MAKE30 in septic participants.

Secondary Outcomes: Incidence of AKI within 7 days and all-cause mortality within 30 days in septic participants.

Detailed Methods:

Case Selection:

participants admitted to the ICU of the participating research units between July, 2024 and ,January，2025 (the participating research units include: West China Hospital of Sichuan University, Sichuan Provincial People's Hospital, Mianyang Third People's Hospital, Affiliated Hospital of Southwest Medical University, Longquanyi District First People's Hospital, Pidu District People's Hospital, Wenjiang District People's Hospital, Xindu District Third People's Hospital,Yibin Second People's Hospital, etc.).

Data Collection:

After the participants were enrolled, participants demographic characteristics were collected: age, gender, height, weight, underlying comorbidities; main diagnosis upon ICU admission, site of infection, microbiological name, baseline serum creatinine level, etc. Collect data on diagnosing sepsis at Day1 (0-24hour), Day2 (24-48hour), Day3 (48-72hour), Day7, and Day30(Including Hemodynamic parameters, respiratory related indicators, neurologic related indicators, renal function indicators, cardiac markers, basic blood tests, infection indicators, severity scores, critical care ultrasound evaluation, Occurrence of AKI in day 7, AKI onset time, criteria, staging, Duration of mechanical ventilation, use of CRRT, vasopressor use, length of ICU stay, length of hospital stay, survival status, occurrence of MAKE30.)

Sample size calculation:

Preliminary calculation includes approximately 120 participants.

Statistical Analysis Methods:

Using SPSS software for statistical analysis. Normality test and homogeneity of variance test were conducted for quantitative data. Data that conform to normal distribution and homogeneity of variance are represented by mean ± standard deviation (x±s). Paired t-test is used for comparison between two groups, while one-way analysis of variance is used for comparison among multiple groups. For quantitative data that do not conform to normal distribution or homogeneity of variance, the median \[interquartile range (IQR)\] is used to represent the data, and non-parametric tests are used for comparison among multiple groups. Count data are expressed as frequency (percentage), and group comparisons are made using Fisher's exact probability test. Multiple logistic regression analysis is used to identify risk factors for AKI in sepsis participants. Receiver operating characteristic (ROC) curve analysis is conducted to assess the predictive value. Cox regression analysis is used to identify risk factors for mortality in sepsis AKI participants. P\<0.05 indicates statistical significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Point-of-care ultrasound (POCUS)

Point-of-care ultrasound (POCUS) measurements will be performed for all participants

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult participants (age ≥ 18 years) with sepsis upon admission or during their stay in the ICU.

Exclusion Criteria

* Age \< 18 years
* Participants admitted to the ICU for \< 24 hours
* Pregnant or lactating women
* Severe renal impairment (defined as baseline estimated glomerular filtration rate \< 15 mL/min or requiring regular dialysis), including causes such as urinary tract obstruction, contrast agents, or nephrotoxic drugs
* Liver cirrhosis with portal hypertension
* Presence of urinary tract obstruction (which may affect IRVF waveform)
* Inability to resolve the primary disease
* Participants receiving palliative care
* Inability to obtain ultrasound images
* Inability to monitor CVP
* Refusal of monitoring by participants or their families

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No